Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 819, Issue -, Pages 30-34Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejphar.2017.11.041
Keywords
Vinpocetine; Inflammation; Neurovascular; Cardiovascular
Categories
Funding
- USA NIH [HL134910, HL088400, DC013833, DC005843]
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088400, R01HL134910] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC015557, R01DC005843, R01DC013833] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Vinpocetine, a derivative of the alkaloid vincamine, has been clinically used in many countries for treatment of cerebrovascular disorders such as stroke and dementia for more than 30 years. Currently, vinpocetine is also available in the market as a dietary supplement to enhance cognition and memory. Due to its excellent safety profile, increasing efforts have been put into exploring the novel therapeutic effects and mechanism of actions of vinpocetine in various cell types and disease models. Recent studies have revealed a number of novel functions of vinpocetine, including anti-inflammation, antagonizing injury-induced vascular remodeling and high-fat-diet-induced atherosclerosis, as well as attenuating pathological cardiac remodeling. These novel findings may facilitate the repositioning of vinpocetine for preventing or treating relevant disorders in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available